systemic juvenile idiopathic arthritis


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.
Related to systemic juvenile idiopathic arthritis: juvenile rheumatoid arthritis

systemic juvenile idiopathic arthritis

A form of JIA that accounts for 20% of all cases; boys are affected 60% of the time. Fever and rash may be the presenting symptoms, either with or without joint involvement. Ultimately, 25% of these children develop severe arthritis.
See also: arthritis
References in periodicals archive ?
Systemic juvenile idiopathic arthritis (SJIA) is a rare form of chronic arthritis in children up to 16 years of age.
* A review of the Systemic Juvenile Idiopathic Arthritis (SJIA) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The US Food and Drug Administration has approved the subcutaneous formulation of Actemra (tocilizumab) for the treatment of active systemic juvenile idiopathic arthritis in patients two years of age and older, US-based biotechnology company Genentech said.
Preliminary evidence for sustained bioactivity of IL-1 Trap (rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis (SJIA).
Novartis announced today that the US Food and Drug Administration (FDA) has approved IlarisA (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older.
Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist.
Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis (SJIA).
These other illnesses were cytomegalovirus (in 21 children), adenovirus (16), systemic juvenile idiopathic arthritis (12), EpsteinBarr virus (5), and staphylococcal scalded skin syndrome (1).
Efficacy and safety of tocilizumab (TCZ) in patients (PTS) with systemic juvenile idiopathic arthritis (SJIA): TENDER 52-week data.
The English medical literature contains no previous reports of systemic juvenile idiopathic arthritis (JIA) presenting with a sterile abscess.
It is also used as an IV formulation for patients with active polyarticular juvenile idiopathic arthritis or systemic juvenile idiopathic arthritis two years of age and older.

Full browser ?